Gregory Glenn
No más puestos en curso
Fortuna: 90 595 $ al 29/02/2024
Perfil
Gregory M. Glenn fundó Intercell USA, Inc. El Dr. Glenn es Presidente de Investigación y Desarrollo de Novavax, Inc. Anteriormente ocupó el cargo de Director Científico de Intercell AG, Director Científico y Vicepresidente Senior de Intercell USA, Inc., Científico de Investigación en el Instituto de Investigación del Ejército Walter Reed y Asociado de Salud Internacional en la Escuela de Salud Pública Bloomberg de Johns Hopkins. El Dr. Glenn se licenció en el Whitman College y se doctoró en la Universidad Oral Roberts.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
NOVAVAX, INC.
0.02% | 18/04/2023 | 18 339 ( 0.02% ) | 90 595 $ | 29/02/2024 |
Antiguos cargos conocidos de Gregory Glenn.
Empresas | Cargo | Fin |
---|---|---|
NOVAVAX, INC. | Chief Tech/Sci/R&D Officer | 31/03/2023 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Chief Tech/Sci/R&D Officer | 01/01/2010 |
IOMAI CORPORATION | Founder | 01/01/2008 |
Walter Reed Army Institute of Research | Corporate Officer/Principal | - |
Johns Hopkins Bloomberg School of Public Health | Corporate Officer/Principal | - |
Formación de Gregory Glenn.
Oral Roberts University | Doctorate Degree |
Whitman College | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
NOVAVAX, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Health Technology |
Intercell USA, Inc.
Intercell USA, Inc. BiotechnologyHealth Technology Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD. | Health Technology |
Walter Reed Army Institute of Research |